DRI Healthcare Trust (TSE:DHT.UN) Receives C$17.94 Consensus Price Target from Brokerages

Shares of DRI Healthcare Trust (TSE:DHT.UN) have been given a consensus rating of “Moderate Buy” by the six ratings firms that are covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is C$17.94.

DHT.UN has been the topic of several research analyst reports. National Bankshares reduced their target price on DRI Healthcare Trust from C$19.50 to C$17.50 and set an “outperform” rating on the stock in a research note on Thursday, February 20th. CIBC reduced their price objective on shares of DRI Healthcare Trust from C$19.50 to C$18.00 and set an “outperform” rating on the stock in a research report on Thursday, December 12th.

DRI Healthcare Trust Price Performance

Shares of DHT.UN opened at C$11.13 on Wednesday. DRI Healthcare Trust has a twelve month low of C$10.39 and a twelve month high of C$17.43. The firm has a fifty day simple moving average of C$11.76 and a two-hundred day simple moving average of C$12.45.

About DRI Healthcare Trust

DRI Healthcare Trust is an open-ended trust that provides unitholders with differentiated exposure to the anticipated growth in the global pharmaceuticals and biotechnology markets. Its business model is focused on managing and growing a diversified portfolio of pharmaceutical royalties to deliver attractive growth in cash royalty receipts over the long term.